Staff shortages at regulatory agencies and potentially overzealous “weeding” of products are two of the issues affecting expedited programs in their mission to deliver accelerated access to innovative new medicines in the US, EU and UK, said regulators at a symposium last week..
Expedited Programs: Overworked Staff & Financial Motives
A shortage of staff and expertise at regulatory agencies as well as tough eligibility criteria can impact expedited programs and their capacity to help deliver quicker access to innovative products.
